Note To: OOC-ACM-303 Study Patients

Regarding: Continued Participation in the Study after Early Discontinuation of Study Drug

Dear Sir or Madam,

You have discontinued receiving study drug before the end of study OOC-ACM-303 (Week 36). We would like to remind you that as part of the original consent for this study, you agreed to continue to attend study visits through the end of Week 36, even if you discontinue receiving the study drug early. Your continued participation is extremely important. We hope this study might assist in bringing an oral treatment to acromegaly patients, however, it is important that all required data be collected to allow meaningful interpretation of study results. Such results are required by regulatory authorities to support their consideration of approving the drug. The information collected during your study visits will be combined with results from other participants prior to analysis.

As part of the study, all aspects of the original consent still apply and you will continue to receive compensation for any remaining visits that you attend. Below is a list of your planned visits through Week 36. We would like to thank you for your continued support of this important research study.

Remaining planned visits:

|  |  |
| --- | --- |
| **Visit Date / Time** | **Visit Name** |
| \_\_\_ / \_\_\_ / 201\_\_\_ \_\_\_\_ : \_\_\_\_\_ | Week 4 |
| \_\_\_ / \_\_\_ / 201\_\_\_ \_\_\_\_ : \_\_\_\_\_ | Week 8 |
| \_\_\_ / \_\_\_ / 201\_\_\_ \_\_\_\_ : \_\_\_\_\_ | Week 12 |
| \_\_\_ / \_\_\_ / 201\_\_\_ \_\_\_\_ : \_\_\_\_\_ | Week 16 |
| \_\_\_ / \_\_\_ / 201\_\_\_ \_\_\_\_ : \_\_\_\_\_ | Week 20 |
| \_\_\_ / \_\_\_ / 201\_\_\_ \_\_\_\_ : \_\_\_\_\_ | Week 24 |
| \_\_\_ / \_\_\_ / 201\_\_\_ \_\_\_\_ : \_\_\_\_\_ | Week 28 |
| \_\_\_ / \_\_\_ / 201\_\_\_ \_\_\_\_ : \_\_\_\_\_ | Week 32 |
| \_\_\_ / \_\_\_ / 201\_\_\_ \_\_\_\_ : \_\_\_\_\_ | Week 36 |